Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

    Rituparna Maiti1, Jyothirmai Jaida1, P. L. John Israel2, Narendar Koyagura1, Sruthi Mukkisa1 Corresponding author

    1. 1Anuradha Palani Departments of Pharmacology.
    2. 2General Medicine, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India Research Paper.

    CORRESPONDENCE

    Rituparna Maiti

    Anuradha Palani Departments of Pharmacology.

    rituparnamaiti@rediffmail.com

    Volume 2, Issue 3 · pp. 150–157 · PUBLISHED 2011 · DOI: 10.4103/0976-500X.83278

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Objective: To compare the effi cacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal refl ux disease (GERD). Materials and Methods: A randomized, single-blinded, outdoor- based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The effi cacy variables were change in GERD symptom scoring, endoscopic fi ndings, and Quality of Life in Refl ux and Dyspepsia (QOLRAD) scoring over 4 weeks. Result: Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were signifi cantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all fi ve domains of the QOLARD questionnaire including overall scoring revealed a statistically signifi cant improvement in the rabeprazole group. Endoscopic fi ndings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no signifi cant difference in the incidence of adverse effects. Conclusion: Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better effi cacy and safety profi le.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Maiti, R., Jaida, J., Israel, P. L. J., Koyagura, N., & Mukkisa, S. (2011). Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. Journal of Pharmacology and Pharmacotherapeutics, 2(3), 150–157. https://doi.org/10.4103/0976-500X.83278